nanoTherics company

NanoTherics gene transfection studies have shown a significant performance enhancement over the best non-viral techniques currently on the market, demonstrating high levels of transfection whilst, importantly, maintaining the viability of the transfected cells. These two key attributes afford a significant competitive advantage over currently available systems.
NanoTherics mission is to position its novel gene transfection technology as the new gold standard for transfection, underpinning the research and development of current and future gene therapy programmes.
Technology: Regenerative Medicine
Industry: Personalized Medicine
Headquarters: Stoke-on-trent, Stoke-on-Trent, United Kingdom
Founded Date: 2007
Employees Number: 11-50
Funding Status: N/A
Investors Number: 3
Total Funding: £1.1M
Estimated Revenue: $1M to $10M
Last Funding Type: Venture - Series Unknown

Visit Website
Register and Claim Ownership